Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

101. A cleaner burning biomass-fuelled cookstove intervention to prevent pneumonia in children under 5 years old in rural Malawi (the Cooking and Pneumonia Study): a cluster randomised controlled trial.

A cleaner burning biomass-fuelled cookstove intervention to prevent pneumonia in children under 5 years old in rural Malawi (the Cooking and Pneumonia Study): a cluster randomised controlled trial. BACKGROUND: WHO estimates exposure to air pollution from cooking with solid fuels is associated with over 4 million premature deaths worldwide every year including half a million children under the age of 5 years from pneumonia. We hypothesised that replacing open fires with cleaner burning biomass (...) -fuelled cookstoves would reduce pneumonia incidence in young children. METHODS: We did a community-level open cluster randomised controlled trial to compare the effects of a cleaner burning biomass-fuelled cookstove intervention to continuation of open fire cooking on pneumonia in children living in two rural districts, Chikhwawa and Karonga, of Malawi. Clusters were randomly allocated to intervention and control groups using a computer-generated randomisation schedule with stratification by site

Lancet2016 Full Text: Link to full Text with Trip Pro

102. Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt

Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt WHO IRIS: Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt Browse Related links Files in This Item: File Description Size Format 305.31 kB Adobe PDF Title: Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt Authors: Issue Date (...) : Dec-2016 Publisher: World Health Organization. Regional Office for the Eastern Mediterranean Journal: EMHJ-Eastern Mediterranean Health Journal, 22 (12): 894-903 Place of publication: Cairo Language: English Abstract: Ventilator-associated pneumonia [VAP] is the most common hospital-acquired infection among mechanically ventilated patients. Our objectives were to determine the incidence of VAP, isolate multidrug-resistant bacteria, identify the most prevalent resistant strains and identify

WHO2016

103. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study.

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Objective To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) and assess whether unmeasured confounding explains this association. Design Cohort study and self controlled case series. Setting Clinical Practice Research Datalink (1990 to 2013) in UK. Participants Adult patients with a new prescription for a PPI (...) individually matched with controls. Main outcome measures Association of community acquired pneumonia with PPI prescription estimated by three methods: a multivariable Cox model comparing risk in PPI exposed patients with controls, corrected for potential confounders; a self controlled case series; and a prior event rate ratio (PERR) analysis over the 12 month periods before and after the first PPI prescription. Results 160 000 new PPI users were examined. The adjusted Cox regression showed a risk

BMJ2016 Full Text: Link to full Text with Trip Pro

104. Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.

Antibiotics for treating community-acquired pneumonia in people with sickle cell disease. BACKGROUND: As a consequence of their condition, people with sickle cell disease are at high risk of developing an acute infection of the pulmonary parenchyma called community-acquired pneumonia. Many different bacteria can cause this infection and antibiotic treatment is generally needed to resolve it. There is no standardized approach to antibiotic therapy and treatment is likely to vary from country (...) to country. Thus, there is a need to identify the efficacy and safety of different antibiotic treatment approaches for people with sickle cell disease suffering from community-acquired pneumonia. This is an update of a previously published Cochrane Review. OBJECTIVES: To determine the efficacy and safety of the antibiotic treatment approaches (monotherapy or combined) for people with sickle cell disease suffering from community-acquired pneumonia. SEARCH METHODS: We searched The Group's

Cochrane2016

105. A semi-synthetic oligosaccharide conjugate vaccine candidate confers protection against Streptococcus pneumoniae serotype 3 infection

A semi-synthetic oligosaccharide conjugate vaccine candidate confers protection against Streptococcus pneumoniae serotype 3 infection 27818299 2017 10 26 2018 11 13 2451-9448 23 11 2016 Nov 17 Cell chemical biology Cell Chem Biol A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. 1407-1416 S2451-9456(16)30356-7 10.1016/j.chembiol.2016.09.016 The identification of immunogenic glycotopes that render glycoconjugate (...) vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides

Cell chemical biology2016 Full Text: Link to full Text with Trip Pro

106. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia

Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia 27471201 2016 07 29 2016 10 03 1399-3003 48 4 2016 Oct The European respiratory journal Eur. Respir. J. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. 1150-1159 10.1183/13993003.00474-2016 In a double-blind, randomised, placebo-controlled trial of hospitalised patients with community-acquired pneumonia (CAP), we demonstrated shorter time to clinical stability (TTCS (...) of the physician. Effect modification was tested with inclusion of interaction terms in the statistical models.Reduced TTCS with prednisone was seen in all microbiological, antibiotic, procalcitonin and afebrile patient subgroups. We found evidence for a different prednisone response in patients with pneumococcal pneumonia in whom intravenous antibiotic duration was not shorter (interaction p=0.01) with prednisone, as was observed in the remaining study population. In patients without macrolide treatment

EvidenceUpdates2016

107. Validation of risk scoring models for predicting stroke-associated pneumonia in patients with ischaemic stroke

Validation of risk scoring models for predicting stroke-associated pneumonia in patients with ischaemic stroke 28959473 2018 11 13 2059-8696 1 3 2016 Sep Stroke and vascular neurology Stroke Vasc Neurol Validation of risk scoring models for predicting stroke-associated pneumonia in patients with ischaemic stroke. 122-126 10.1136/svn-2016-000025 Various risk scoring models have been developed to predict stroke-associated pneumonia (SAP). We aim to determine whether these risk models could (...) effectively predict SAP in Chinese patients with ischaemic stroke (IS). Consecutive patients with IS in West China hospital between January 2011 and September 2013 were included to assess the predictive performance of risk scoring models, including Chumbler's score, A 2 DS 2 and AISAPS. The area under the receiver operating characteristic curve (AUROC) was used to evaluate the performance of each risk model in predicting pneumonia. A total of 1569 consecutive patients with IS within 30 days of onset

Stroke and vascular neurology2016 Full Text: Link to full Text with Trip Pro

108. Ventilator associated events should trump ventilator associated pneumonia

Ventilator associated events should trump ventilator associated pneumonia 28979524 2018 11 13 1751-1437 17 4 2016 Nov Journal of the Intensive Care Society J Intensive Care Soc Ventilator associated events should trump ventilator associated pneumonia. 358 10.1177/1751143716651290 Thomas Matt M Intensive Care Medicine, North Bristol NHS Trust, Bristol, UK. eng Journal Article 2016 10 25 England J Intensive Care Soc 101538668 1751-1437 Lancet. 1999 Nov 27;354(9193):1851-8 10584721 Crit Care Med

Journal of the Intensive Care Society2016 Full Text: Link to full Text with Trip Pro

109. Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals

Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals 28053969 2018 11 13 2312-0541 2 4 2016 Oct ERJ open research ERJ Open Res Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals. 00011-2016 10.1183/23120541.00011-2016 The pneumocococcal urine antigen test increases specific microbiological diagnosis over conventional culture methods in pneumonia patients. Data are limited regarding its yield (...) and effect on antibiotic prescribing among patients with community-onset pneumonia in clinical practice. We performed a secondary analysis of 2837 emergency department patients admitted to seven Utah hospitals over 2 years with international diagnostic codes version 9 codes and radiographic evidence of pneumonia. Mean age was 64.2 years, 47.2% were male and all-cause 30-day mortality was 9.6%. Urinary antigen testing was performed in 1110 (39%) patients yielding 134 (12%) positives. Intensive

ERJ open research2016 Full Text: Link to full Text with Trip Pro

110. Predicting 2-Year Risk of Developing Pneumonia in Older Adults without Dementia

Predicting 2-Year Risk of Developing Pneumonia in Older Adults without Dementia 27401847 2016 07 12 2017 04 27 1532-5415 64 7 2016 Jul Journal of the American Geriatrics Society J Am Geriatr Soc Predicting 2-Year Risk of Developing Pneumonia in Older Adults without Dementia. 1439-47 10.1111/jgs.14228 To develop three prognostic indices of varying degree of required detail for 2-year pneumonia risk in older adults. Retrospective cohort study. Group Health (GH), an integrated healthcare delivery (...) system. Community-dwelling dementia-free individuals aged 65 and older who had been GH members for at least 2 years before start of follow-up and were enrolled in the Adult Changes in Thought study (N = 3,375; development cohort, n = 2,250; validation cohort, n = 1,125. Potential pneumonia risk factors were identified from questionnaire data and interviewer assessments of functional status, medical history, smoking and alcohol use, cognitive function, personal care, and problem solving. Risk factors

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

111. Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias

Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias - GOV.UK GOV.UK uses cookies to make the site simpler. Search Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias From: Published: 8 August 2016 Therapeutic area: and Patients (...) with pulmonary hypertension associated with idiopathic interstitial pneumonias should not be treated with riociguat in light of interim results from a recently terminated study. Contents Advice for healthcare professionals: patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) should not be treated with riociguat. PH-IIP is not authorised indication for riociguat riociguat treatment should be discontinued in any patient with PH-IIP. The patient’s clinical status

MHRA Drug Safety Update2016

112. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis

Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2016

113. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial

Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial 27455166 2016 09 07 2017 02 02 2168-6114 176 9 2016 Sep 01 JAMA internal medicine JAMA Intern Med Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. 1257-65 10.1001/jamainternmed.2016.3633 The optimal duration of antibiotic treatment for community-acquired pneumonia (CAP) has not been well established. To validate Infectious Diseases

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

114. Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury

Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury 26743488 2016 04 02 2017 02 09 2017 02 09 1399-3003 47 4 2016 Apr The European respiratory journal Eur. Respir. J. Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury. 1219-28 10.1183/13993003.01314-2015 Issues regarding recommendations on empiric antimicrobial therapy for ventilator-associated pneumonia (VAP) have emerged in specific populations.To develop and validate a score (...) Respir J 8803460 0903-1936 0 Anti-Bacterial Agents IM Eur Respir J. 2016 Apr;47(4):1060-1 27037317 Adult Anti-Bacterial Agents therapeutic use Area Under Curve Brain Injuries complications therapy Burns complications therapy Drug Resistance, Bacterial Female Glasgow Coma Scale Humans Incidence Intensive Care Units Male Middle Aged Multivariate Analysis Pneumonia, Ventilator-Associated drug therapy etiology Predictive Value of Tests Prospective Studies Severity of Illness Index Time Factors 2015 08 08

EvidenceUpdates2016

115. Inpatient rehabilitation improves functional capacity, peripheral muscle strength and quality of life in patients with community-acquired pneumonia: a randomised trial

Inpatient rehabilitation improves functional capacity, peripheral muscle strength and quality of life in patients with community-acquired pneumonia: a randomised trial 26996093 2016 04 08 2017 01 19 2017 01 19 1836-9561 62 2 2016 Apr Journal of physiotherapy J Physiother Inpatient rehabilitation improves functional capacity, peripheral muscle strength and quality of life in patients with community-acquired pneumonia: a randomised trial. 96-102 10.1016/j.jphys.2016.02.014 S1836-9553(16)00023-0 (...) Among people who are hospitalised for community-acquired pneumonia, does an inpatient exercise-based rehabilitation program improve functional outcomes, symptoms, quality of life and length of hospital stay more than a respiratory physiotherapy regimen? Randomised trial with concealed allocation, intention-to-treat analysis and blinding of some outcomes. Forty-nine adults hospitalised for community-acquired pneumonia. The experimental group (n=32) underwent a physical training program that included

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

116. Antibiotic preferences for childhood pneumonia vary by physician type and European region

Antibiotic preferences for childhood pneumonia vary by physician type and European region 27730183 2018 11 13 2312-0541 2 2 2016 Apr ERJ open research ERJ Open Res Antibiotic preferences for childhood pneumonia vary by physician type and European region. 00001-2016 Survey of EAPRASnet and @PREPARE_EUROPE members reveals heterogeneity of antibiotic choice for childhood pneumonia http://ow.ly/4mIS2P. Bielicki Julia A JA Paediatric Infectious Diseases Research Group, Institute for Infection

ERJ open research2016 Full Text: Link to full Text with Trip Pro

117. The Intensive Care Society recommended bundle of interventions for the prevention of ventilator-associated pneumonia

The Intensive Care Society recommended bundle of interventions for the prevention of ventilator-associated pneumonia 28979497 2018 11 13 1751-1437 17 3 2016 Aug Journal of the Intensive Care Society J Intensive Care Soc The Intensive Care Society recommended bundle of interventions for the prevention of ventilator-associated pneumonia. 238-243 10.1177/1751143716644461 Ventilator-associated pneumonia is an important healthcare-associated infection. Interventions for the prevention of ventilator (...) -associated pneumonia are often used within bundles of care. Recent evidence has challenged widespread practices mandating a review of subject. This article outlines guidance for ventilator-associated pneumonia prevention. Hellyer Thomas P TP Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. Ewan Victoria V Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. Wilson Peter P Clinical Microbiology and Virology, University College London Hospitals NHS

Journal of the Intensive Care Society2016 Full Text: Link to full Text with Trip Pro

118. CURB-65 Performance among Admitted and Discharged Emergency Department Patients with Community Acquired Pneumonia

CURB-65 Performance among Admitted and Discharged Emergency Department Patients with Community Acquired Pneumonia 26825484 2016 04 09 2016 10 20 2016 12 30 1553-2712 23 4 2016 Apr Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med CURB-65 Performance Among Admitted and Discharged Emergency Department Patients With Community-acquired Pneumonia. 400-5 10.1111/acem.12929 Pneumonia severity tools were primarily developed in cohorts (...) of hospitalized patients, limiting their applicability to the emergency department (ED). We describe current community ED admission practices and examine the accuracy of the CURB-65 to predict 30-day mortality for patients, either discharged or admitted with community-acquired pneumonia (CAP). A retrospective, observational study of adult CAP encounters in 14 community EDs within an integrated healthcare system. We calculated CURB-65 scores for all encounters and described the use of hospitalization

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

119. Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia

Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia 26469764 2016 02 13 2016 06 20 2017 01 14 1535-4970 193 4 2016 Feb 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia. 448-59 10.1164/rccm.201506-1100OC Plasma-detectable biomarkers that rapidly and accurately diagnose bacterial infections in children (...) with suspected pneumonia could reduce the morbidity of respiratory disease and decrease the unnecessary use of antibiotic therapy. Using 56 markers measured in a multiplexed immunoassay, we sought to identify proteins and protein combinations that could discriminate bacterial from viral or malarial diagnoses. We selected 80 patients with clinically diagnosed pneumonia (as defined by the World Health Organization) who also met criteria for bacterial, viral, or malarial infection based on clinical

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

120. Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran)

Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran) 27123215 2016 04 28 2018 11 13 2008-5842 8 3 2016 Mar Electronic physician Electron Physician Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran). 2081-7 10.19082/2081 Production (...) of extended spectrum beta lactamase (ESBL) is an important mechanism of antimicrobial resistance in Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) isolates. This study was performed to determine the prevalence and risk factors associated with ESBL producing strains of E. coli and K. pneumoniae. In this cross-sectional study, 250 strains (134 E. coli and 116 K. pneumoniae) were obtained, and ESBL producing isolates were detected by the combination disk test in Shahid Beheshti Hospital

Electronic physician2016 Full Text: Link to full Text with Trip Pro